6-[(1-fluoro-1-hydroxypropan-2-yl)oxymethyl]-5-methyl-1H-pyrimidine-2,4-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 6-[(1-fluoro-1-hydroxypropan-2-yl)oxymethyl]-5-methyl-1H-pyrimidine-2,4-dione
• 化学式: C₉H₁₃FN₂O₄
• 分子量: 232.21
• InChiKey: ZRVODDWNQXHVFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  87.7
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Thymidine kinase diagnostic assay for gene therapy applications
  申请人：GenVivo, Inc.

  公开号：US11253611B2

  公开（公告）日：2022-02-22

  Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.

  提供了编码改良的单纯疱疹病毒胸苷激酶的核酸序列，包括它们在诊断和治疗中的应用。胸苷激酶可通过保守突变、非保守突变或两者兼而有之的方式进行突变。还提供了基因治疗系统，包括病毒和逆转录病毒颗粒。
• THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS
  申请人：Epeius Biotechnologies Corporation

  公开号：EP2967078A1

  公开（公告）日：2016-01-20
• IMPROVED THYMIDINE KINASE GENE
  申请人：Epeius Biotechnologies Corporation

  公开号：EP2970945A2

  公开（公告）日：2016-01-20
• [EN] IMPROVED THYMIDINE KINASE GENE<br/>[FR] GÈNE CODANT POUR DES THYMIDINE KINASES AMÉLIORÉES
  申请人：EPEIUS BIOTECHNOLOGIES CORP

  公开号：WO2014153258A2

  公开（公告）日：2014-09-25

  Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.
• [EN] THYMIDINE KINASE DIAGNOSTIC ASSAY FOR GENE THERAPY APPLICATIONS<br/>[FR] DOSAGE DIAGNOSTIQUE DES THYMIDINE KINASES POUR APPLICATIONS DE THÉRAPIE GÉNIQUE
  申请人：EPEIUS BIOTECHNOLOGIES CORP

  公开号：WO2014153205A1

  公开（公告）日：2014-09-25

  Nucleic acid sequences encoding improved Herpes Simplex Virus Thymidine Kinases are provided, including their use in diagnostic and therapeutic applications. The thymidine kinases may be mutated using conservative mutations, non-conservative mutations, or both. Also provided are gene therapeutic systems, including viral and retroviral particles.